Table 4.
Characteristics of the studies about UC patients included in the meta-analysis.
| Author | Year | Location | Region | Data Source | n. of PC/Patients with UC | n. of PC/Control Population | RR | 95%CI |
|---|---|---|---|---|---|---|---|---|
| Karlèn et al. [15] | 1999 | Sweden | Stockholm | C.R. | 7/1547 | 11,526/1,783,000 | 0.70 | 0.33–1.47 |
| Bernstein et al. [16] | 2001 | Canada | Manitoba | C.R. | 19/2672 | 8438/1,151,000 | 0.97 | 0.62–1.52 |
| Winther et al. [17] | 2004 | Denmark | Copenhagen | P.B.C. | 4/1160 | 2598/557,500 | 0.74 | 0.28–1.94 |
| Hemminki et al. [18] | 2008 | Sweden | Sweden | C.R. | 277/27,606 | 79,005/8,976,000 | 1.14 | 1.01–1.28 |
| Jussila et al. [13] | 2013 | Finland | Finland | C.R. | 150/16,649 | 56,718/5,351,000 | 0.85 | 0.73–1.00 |
| Kappelman et al. [10] | 2014 | Denmark | Denmark | C.R. | 258/35,152 | 33,976/5,554,844 | 1.21 | 1.08–1.35 |
| Wilson et al. [20] | 2016 | UK | UK | CPRD | 62/11,797 | 51/11,797 | 1.21 | 0.84–1.76 |
| Jung et al. [21] | 2017 | Korea | Korea | HIRA-d | 18/9787 | 26,904/50,750,000 | 3.47 | 2.19–5.51 |
| So et al. [22] | 2017 | H.K. | H.K. | IBD-d | 8/1603 | 14,936/7,392,000 | 2.47 | 1.24–4.93 |
UK: United Kingdom; H.K.: Hong Kong; C.R.: cancer register; P.B.C.: population-based cohort; CPRD: clinical practice research Datalink; HIRA-d: Health Insurance and Review Agency database; IBD: inflammatory bowel disease; n= number; PC: prostate cancer; UC: ulcerative colitis; RR: relative risk; CI: confidence intervals.